HilleVax Investor Relations Material

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The company’s primary product under development is HIL-214, a virus-like particle-based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax has been working on advancing this vaccine through clinical trials, with efforts to evaluate its safety and efficacy across different age groups. Hillevax is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.